What is BPC-157? A Research Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — representing a partial sequence of a protein found in human gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), with a molecular weight of roughly 1,419 Da. This overview covers what the preclinical literature actually reports; for a deeper comparison against a related recovery-research peptide, see BPC-157 vs TB-500, and for the pharmacokinetic data specifically, see BPC-157 half-life explained.

Research Background

BPC-157 has been studied in laboratory and animal-model settings since the early 1990s, with much of the foundational work conducted by Predrag Sikiric and colleagues at the University of Zagreb. The compound was first described in the context of gastric cytoprotection research and has since been examined across a range of preclinical models — tendon and ligament healing, gastrointestinal mucosal protection, and vascular biology among them.

Structure and Chemical Stability

BPC-157's sequence is unusually rich in proline and glycine, which gives the peptide a compact, resistant conformation. Review literature describes it as remaining stable in human gastric juice — an aggressively acidic, protease-rich environment — for more than 24 hours in laboratory testing, in contrast to most peptides, which are degraded within minutes by stomach acid and pepsin. This intrinsic chemical stability is a property of the molecule itself and is separate from its biological half-life once introduced systemically (see the half-life article linked above for that distinction).

Proposed Mechanisms in Preclinical Models

Preclinical studies have associated BPC-157 with several signaling pathways, though the full mechanistic picture is still being worked out in the literature:

• Angiogenesis — associated with activation and up-regulation of VEGFR2 (vascular endothelial growth factor receptor 2), with downstream signaling through the Akt–eNOS axis, mechanisms central to new blood-vessel formation in animal and cell models.
• Growth hormone receptor expression — in-vitro work in tendon fibroblasts has reported enhanced growth hormone receptor expression, a pathway relevant to connective-tissue repair research.
• Nitric oxide system — some studies report modulation of nitric-oxide-related signaling alongside the angiogenic findings above.

Key Research Areas

• Tendon and ligament fibroblast models — cell proliferation and migration studies relevant to connective-tissue repair research.
• Gastrointestinal mucosa — protective effects studied in rat models of gastric ulceration, the compound’s original research context.
• Neurological models — dopaminergic and serotonergic pathway studies in animal models, an active but less-established research area.
• Angiogenesis — vascular endothelial growth factor (VEGF) pathway studies in wound-healing and tissue-repair models.
• Systemic administration studies — intraperitoneal and subcutaneous routes studied in rodent models to characterize distribution and effect.

What the Pharmacokinetic Data Shows

A 2022 pharmacokinetic study characterized BPC-157's disposition in rats and dogs, reporting a mean elimination half-life of approximately 15.2 minutes after intravenous dosing in rats, with intramuscular bioavailability on the order of 14–19%, and clearance primarily via urine and bile with hepatic breakdown into constituent amino acids. That short plasma window is frequently misread as meaning the compound's effects are similarly brief — they are not the same measurement. See BPC-157 half-life explained for the full breakdown of why a short plasma clearance time doesn't equal a short duration of biological effect in the preclinical literature.

Supply and Storage

Research-grade BPC-157 is typically supplied as a lyophilized (freeze-dried) white powder in sealed, sterile vials. Purity should be verified by HPLC at ≥98%, with sequence identity confirmed by mass spectrometry. Lyophilized BPC-157 is stable at room temperature for up to 24 months. Once reconstituted in bacteriostatic water, it should be refrigerated at 2–8°C and used within 28 days, avoiding freeze-thaw cycles. See how to reconstitute research peptides for the full technique.

What to Look for in a Supplier

• HPLC purity ≥98% from an independent third-party laboratory
• Mass spectrometry identity confirmation (sequence verification)
• Lot-specific COA — not a generic company certificate
• Lot number on the vial label matching the COA

Research Use Only

BPC-157 is sold and discussed here strictly for laboratory and preclinical research. Nothing in this article describes or implies a human dosing protocol, administration method, or therapeutic application. Every lot we ship is third-party HPLC tested and lot-tracked — confirm any lot on our verification page.